Last reviewed · How we verify
AZD7009, no generic name available
AZD7009 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD7009 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | AZD7009, no generic name available |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD7009 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Headache
- Musculoskeletal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD7009, no generic name available CI brief — competitive landscape report
- AZD7009, no generic name available updates RSS · CI watch RSS
- AstraZeneca portfolio CI